PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30765854-5	2019	We present a combinatorial PIT approach for targeting BC expressing EGFR and HER2, using PA- labeled panitumumab (pan) and trastuzumab (tra), respectively.	Protactinium	89-91	erb-b2 receptor tyrosine kinase 2	Homo sapiens	77-81	
26238078-6	2015	We propose 20-nm anti-HER2 scFv-conjugated IONPs (SNP20) as a novel PA contrast agent.	Protactinium	68-70	erb-b2 receptor tyrosine kinase 2	Homo sapiens	22-26	
26238078-8	2015	These data indicate that SNP20 is a potential PA contrast agent for imaging of HER2-expressing tumors.	Protactinium	46-48	erb-b2 receptor tyrosine kinase 2	Homo sapiens	79-83	
22486195-4	2012	HER2 amplification was more prevalent in extracapsular CXPAs (9/18 cases; 50%) than intracapsular CXPAs (1/5 cases; 20%), intraductal CXPAs (2/8 cases; 25%), or atypical PAs (0/7 case; 0%).	Protactinium	57-60	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-4	
25442282-3	2014	AIMS: To test whether the anti-proliferative activity of (+)-PA is associated with effects on FASN and HER2 (human epidermal growth factor receptor 2) and major signalling pathways.	Protactinium	57-63	erb-b2 receptor tyrosine kinase 2	Homo sapiens	103-107	
25442282-3	2014	AIMS: To test whether the anti-proliferative activity of (+)-PA is associated with effects on FASN and HER2 (human epidermal growth factor receptor 2) and major signalling pathways.	Protactinium	57-63	erb-b2 receptor tyrosine kinase 2	Homo sapiens	115-149	
25442282-10	2014	RESULTS: Treatment with (+)-PA increased FASN expression in SK-BR-3 cells, which overexpress FASN and HER2, implying a compensatory response to inhibition of FASN activity.	Protactinium	24-30	erb-b2 receptor tyrosine kinase 2	Homo sapiens	102-106	
25442282-16	2014	Synergistic effects with lapatinib were seen only in SK-BR-3 cells, and not T-47D cells, further supporting the notion that (+)-PA acts by inhibiting FASN with secondary effects on HER2 expression and signalling.	Protactinium	124-130	erb-b2 receptor tyrosine kinase 2	Homo sapiens	181-185	
25442282-17	2014	(+)-PA could therefore be a suitable agent for further testing, alone or in combination treatment against HER2-overexpressing breast cancer.	Protactinium	0-6	erb-b2 receptor tyrosine kinase 2	Homo sapiens	106-110	
17703668-3	2007	In this study, PA imaging of multiple targets using gold nanorods is demonstrated experimentally using HER2 and CXCR4 as target molecules.	Protactinium	15-17	erb-b2 receptor tyrosine kinase 2	Homo sapiens	103-107	
21317706-5	2011	HER2 expression, p53 expression, and the Ki-67 labeling index were higher in CXPAs than in atypical PAs and conventional PAs, whereas the AR expression level was relatively high even in atypical PAs.	Protactinium	79-82	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-4	
15722572-2	2005	The purpose of this study was to compare the prevalence of K-ras and c-erbB-2 mutations in PA and CP in order to evaluate their usefulness in differential diagnosis of those diseases.	Protactinium	91-93	erb-b2 receptor tyrosine kinase 2	Homo sapiens	69-77	
15722572-6	2005	Prevalence of c-erbB-2 amplification in patients with PA was 17 (65.3%), which was not different from CP, 16 (56.5%) (p=0.58).	Protactinium	54-56	erb-b2 receptor tyrosine kinase 2	Homo sapiens	14-22	
32679213-7	2020	In an cellular uptake study, Tra-Lipo-IONPs were taken up by HER2-positive tumor cells and HER2-specific MR/PA dual imaging was achieved.	Protactinium	108-110	erb-b2 receptor tyrosine kinase 2	Homo sapiens	91-95	
32679213-9	2020	In conclusion, we demonstrated the usefulness of Lipo-IONPs as platforms for sensitive MR/PA dual imaging and the possibility of HER2-specific tumor MR/PA imaging using Tra-Lipo-IONPs.	Protactinium	152-154	erb-b2 receptor tyrosine kinase 2	Homo sapiens	129-133